The team at Morgans has been busy looking at its financial models for a number of ASX dividend stocks.
Two that have fared well and been given buy ratings following their results releases are named below. Here’s why Morgans remains bullish on these stocks:
IPH Ltd (ASX: IPH)
Morgans continues to recommend this intellectual property services company to clients.
In response to its half-year results, the broker has put a buy rating and $5.39 price target on the ASX dividend stock. It said:
IPH’s 1H26 result was broadly in line with consensus, reporting like-for-like (LFL) revenue and EBITDA growth at the group level. Whilst Canada and Asia showed growth, ANZ remains impacted by lower US PCT filings. IPH’s valuation is undemanding (<8x FY27F PE), however we note investor patience is required given the delivery of organic growth (and return of key US PCT’s) looks to be the catalyst for a sustained re-rating. Maintain Buy recommendation.
As for income, Morgans is forecasting fully franked dividends of 38 cents per share in FY 2026 and then 39 cents per share in FY 2027. Based on its current share price of $3.67, this equates to very generous dividend yields of 10.3% and 10.6%, respectively.
Sonic Healthcare Ltd (ASX: SHL)
Another ASX dividend stock that is rated highly by the team at Morgans is Sonic Healthcare.
It responded to its better than expected half-year results by retaining its buy rating with a trimmed price target of $28.64. It said:
1HFY26 result was better than expected, with underlying NPAT c4% ahead and organic revenue growth of 5%, demonstrating resilience across most regions. Underlying EBITDA was broadly in line, margins expanded and cost discipline remained evident. Importantly, FY26 guidance was maintained, an operational review of the US business is underway, and sale-and-leaseback activity introduces capital management optionality.
While structural growth remains moderate, we view the result as evidence that the market’s “broken core” narrative has been overstated. Execution now becomes the key driver, but at subdued trading levels, the risk/reward skews favourably. We adjust FY26-28 estimates (mainly FX related), with our target price decreasing to A$28.64. BUY.
With respect to income, the team at Morgans is expecting Sonic Healthcare to reward shareholders with dividends per share of $1.08 in FY 2026 and then $1.11 in FY 2027. Based on its current share price of $23.02, this would mean dividend yields of 4.7% and 4.8%, respectively.
The post Morgans says these buy-rated ASX dividend stocks offer yields up to 10% appeared first on The Motley Fool Australia.
Should you invest $1,000 in IPH Ltd right now?
Before you buy IPH Ltd shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and IPH Ltd wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- These are the 10 most shorted ASX shares
- Is this ASX 200 healthcare share a great buy after reporting?
- These ASX 200 shares could rise 20% to 40%
- Here are the top 10 ASX 200 shares today
- 2 ASX shares tipped to soar 50% (or more) higher in 2026
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended IPH Ltd and Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.